结节性淋巴细胞为主型霍奇金淋巴瘤的国际预后评分
这项国际回顾性研究纳入1992至2021年38家机构的2243例结节性淋巴细胞为主型霍奇金淋巴瘤患者,中位年龄37岁,中位随访6.3年。免疫架构模式与无进展生存和总生存无关,但E型转化风险升高(HR 1.81)。研究建立淋巴细胞为主型国际预后评分(LP-IPS),年龄≥45岁、III-IV期、血红蛋白<10.5 g/dL和脾受累各1分,评分升高与更差的无进展生存(HR 1.52)、总生存(HR 2.31)、淋巴瘤特异死亡(HR 2.63)和转化(HR 1.41)相关。
要点
- LP-IPS包括年龄≥45岁、III-IV期、血红蛋白<10.5 g/dL和脾受累,各1分。
- LP-IPS升高与更差的无进展生存(HR 1.52)和总生存(HR 2.31)相关。
- 免疫架构模式E与更高的转化风险相关(HR 1.81;P < .05)。
核心结论
- 在这项覆盖各年龄段NLPHL患者的综合研究中,研究者建立LP-IPS以识别高危患者,并为评估低LP-IPS评分(<2)患者降阶梯治疗的前瞻性临床试验提供依据。
研究设计与样本
- 全球nLPHLOne工作组回顾性研究,38家机构参与,纳入1992至2021年NLPHL病例。
- 共纳入2243例患者,中位年龄37岁(IQR,23-51),中位随访6.3年(IQR,3.4-10.8)。
主要发现
- 多数患者为I-II期(72.9%),少数有B症状(9.9%)或脾受累(5.4%)。
- 916例(40.8%)进行了免疫架构模式评分。
- 10年无进展生存率70.8%、总生存率91.6%、转化率4.8%、淋巴瘤特异死亡率3.3%。
- 多变量分析中免疫架构模式与无进展生存或总生存无关,但E型转化风险更高(HR 1.81;P < .05)。
- LP-IPS评分升高与更差的无进展生存(HR 1.52)、总生存(HR 2.31)、淋巴瘤特异死亡风险(HR 2.63)和转化风险(HR 1.41)显著相关。
关键数值与推荐
- LP-IPS评分项目:年龄≥45岁、III-IV期、血红蛋白<10.5 g/dL、脾受累,各1分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for all stages of pediatric and adult patients with NLPHL. METHODS: Thirty-eight institutions participated in the Global nLPHL One Working Group retrospective study of NLPHL cases from 1992 to 2021. We measured progression-free survival (PFS), overall survival (OS), transformation rate, and lymphoma-specific death rate. We performed uni- and multivariable (MVA) Cox regression stratified by management to select factors for the lymphocyte-predominant international prognostic score (LP-IPS) validated by five-fold cross-validation. RESULTS: We identified 2,243 patients with a median age of 37 years (IQR, 23-51). The median follow-up was 6.3 years (IQR, 3.4-10.8). Most had stage I to II (72.9%) and few B symptoms (9.9%) or splenic involvement (5.4%). IAP was scored for 916 (40.8%). Frontline management included chemotherapy alone (32.4%), combined modality therapy (30.5%), radiotherapy alone (24.0%), observation after excision (4.6%), rituximab alone (4.0%), active surveillance (3.4%), and rituximab and radiotherapy (1.1%). The PFS, OS, transformation, and lymphoma-specific death rates at 10 years were 70.8%, 91.6%, 4.8%, and 3.3%, respectively. On MVA, IAPs were not associated with PFS or OS, but IAP E had higher risk of transformation (hazard ratio [HR], 1.81; P < .05). We developed the LP-IPS with 1 point each for age ≥45 years, stage III-IV, hemoglobin <10.5 g/dL, and splenic involvement. Increasing LP-IPS was significantly associated with worse PFS (HR, 1.52) and OS (HR, 2.31) and increased risk of lymphoma-specific death (HR, 2.63) and transformation (HR, 1.41). CONCLUSION: In this comprehensive study of all ages of patients with NLPHL, we develop the LP-IPS to identify high-risk patients and inform upcoming prospective clinical trials evaluating de-escalation of therapy for patients with low LP-IPS scores (<2).
引用
- Binkley MS, Flerlage JE, Savage KJ, et al. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. J Clin Oncol. 2024. PMID: 38531001. doi:10.1200/JCO.23.01655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。